The neurohormonal network in the RAAS can bend before breaking

Current Heart Failure Reports

Volumn 9, Issue 2, 2012, Pages 81-91

  Wagman, Gabriel ^a   Fudim, Marat ^b   Kosmas, Constantine E ^c   Panni, Robert E ^d   Vittorio, Timothy J ^a  

^a ST FRANCIS HOSPITAL   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

Aldosterone synthase inhibitor; Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Angiotensin type 2 receptor agonist; Combination drug therapy; Direct renin inhibitor; Mineralocorticoid receptor blocker; Neurohormonal network; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; EPLERENONE; HORMONE RECEPTOR BLOCKING AGENT; LCI 699; LOSARTAN; METOPROLOL; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; NEUROHORMONE; PLACEBO; PRORENIN RECEPTOR BLOCKING AGENT; RAMIPRIL; RECEPTOR BLOCKING AGENT; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CARDIOVASCULAR AGENT;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BLOOD PRESSURE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG WITHDRAWAL; HEART; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; NONHUMAN; ORGAN BLOOD FLOW; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STARVATION; STROKE; SYNCOPE; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG EFFECT; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84864884864     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0091-y     Document Type: Article

References (75)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med, 1987. 316(23): p. 1429-35.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med, 1991. 325(5): p. 293-302.
3. Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-77.
4. Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
5. Krum H, Maggioni A. Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. Clin Cardiol. 2010;33(9):536-41.
6. Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355 (9215):1582-7. (Pubitemid 30240502)
7. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. (Pubitemid 29407370)
8. Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. (Pubitemid 36384098)
9. Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
10. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides. 2005;26(8):1401-9. (Pubitemid 41021474)
11. Rompe, F., et al., Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension, 2010. 55(4): p. 924-31. This study reports the positive findings of in vitro application of the novel angiotensin II type 2 receptor agonist.
12. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2010;11(1):19-31.
13. Harada S, et al. Contrasting effects of angiotensin type 1 and 2 receptors on nitric oxide release under pressure. Hypertens Res. 2002;25(5):779-86. (Pubitemid 35153768)
14. Oishi Y, et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension. 2003;41(3 Pt 2):814-8. (Pubitemid 36314596)
15. Macari D, et al. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodiumdepleted rat. Eur J Pharmacol. 1993;249(1):85-93.
16. Wan Y, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47(24):5995-6008. (Pubitemid 39507341)
17. Kaschina E, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the reninangiotensin system in myocardial infarction? Circulation. 2008;118(24):2523-32.
18. Colombo PC, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005;111(1):58-62. (Pubitemid 40070844)
19. Calhoun, D.A., et al., Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation, 2011. 124(18): p. 1945-55. This study is the first phase 2 clinical trial to provide evidence for the cardiovascular benefit of the novel aldosterone synthase inhibitor.
20. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol. 2009;308(1-2):53-62.
21. Good DW. Nongenomic actions of aldosterone on the renal tubule. Hypertension. 2007;49(4):728-39. (Pubitemid 351664211)
22. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005;70(5-7):347-51. (Pubitemid 40616031)
23. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol. 2008;93(5):557-63. (Pubitemid 351595066)
24. Nguyen G, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109(11):1417-27. (Pubitemid 34596167)
25. Suzuki F, et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem. 2003;278(25):22217-22. (Pubitemid 36830267)
26. Ichihara A, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114(8):1128-35. (Pubitemid 39578702)
27. Ichihara A, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension. 2006;47(5):894-900. (Pubitemid 44297561)
28. Oparil S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, doubleblind trial. Lancet. 2007;370(9583):221-9. (Pubitemid 47069535)
29. Azizi M, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15(12):3126-33. (Pubitemid 39578845)
30. Vergaro G, et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol. 2011;108(2):246-51.
31. Latini R, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25(4):292-9. (Pubitemid 38295437)
32. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16(3):592-9. (Pubitemid 41725095)
33. Brown MJ. Aliskiren. Circulation. 2008;118(7):773-84.
34. Westermann D, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52(6):1068-75.
35. Pilz B, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46 (3):569-76. (Pubitemid 41376839)
36. Connelly, K., et al., The direct renin inhbitor, aliskerin, improves cardiac function via direct renin inhibition and via renin receptor modulation in a rodent model of diabetic diastolic heart failure. Circulation, 2008. 118: p. S1166. Abstract 6248.
37. Seed A, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail. 2007;9(11):1120-7. (Pubitemid 47633316)
38. McMurray JJ, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1(1):17-24.
39. Solomon SD, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530-7.
40. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation, 1998. 97(22): p. 2202-12.
41. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. (Pubitemid 33126822)
42. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115 (6):473-9. (Pubitemid 37237561)
43. Pfeffer MA, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997;95(12):2643-51. (Pubitemid 27255493)
44. Pfeffer MA, Hennekens CH. When a question has an answer: rationale for our early termination of the HEART Trial. Am J Cardiol. 1995;75(16):1173-5.
45. Latini R, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995;92(10):3132-7.
46. McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-71. (Pubitemid 37093916)
47. Pfeffer MA, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. (Pubitemid 37409706)
48. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181-8. (Pubitemid 351434594)
49. Mann JF, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-53.
50. Montezano AC, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008;28(8):1511-8.
51. Yamamoto E, et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009;54(3):633-8.
52. Dong YF, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010;28 (7):1554-65.
53. Uresin Y, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190-8. (Pubitemid 351166266)
54. Berlowitz MS, et al. Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers. J Cardiovasc Pharmacol. 2001;37(6):692-6. (Pubitemid 32480437)
55. Parving HH, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-46.
56. Vaidyanathan S, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. (Pubitemid 351969826)
57. Oh BH, et al. Aliskiren, an oral renin inhibitor, provides dosedependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49(11):1157-63.
58. Vasan RS, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41.
59. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150(11):776-83.
60. Association, T.A.H., Novartis announces termination of ALTITUDE study with Rasliez/Tekturna in high-risk patients with diabetes and renal impairment., 2011.
61. van Zwieten PA, de Jonge A. Interaction between the adrenergic and renin-angiotensin-aldosterone-systems. Postgrad Med J. 1986;62 Suppl 1:23-7. (Pubitemid 16057508)
62. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 1984;2 (6):581-7. (Pubitemid 15188008)
63. Batenburg, W.W., et al., Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade. J Hypertens, 2006. 24(7): p. 1355-63. This elegant study mechanistically proves the crosstalk phenomenon between the AT1R and the α-1R. (Pubitemid 43948335)
64. De Jonge A, et al. Effect of captopril on sympathetic neurotransmission in pithed normotensive rats. Eur J Pharmacol. 1983;88(2-3):231-40. (Pubitemid 13121913)
65. Henegar JR, et al. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol. 1995;269(5 Pt 2):H1564-9.
66. Marano G, Argiolas L. Postjunctional regulation by angiotensin II of alpha 1-adrenoceptor-mediated pressor responses in the rat. Eur J Pharmacol. 1994;261(1-2):121-6. (Pubitemid 24263211)
67. Lang CC, et al. Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man. J Hypertens. 1992;10(11):1387-95.
68. Hu ZW, et al. Angiotensin II induces transcription and expression of alpha 1-adrenergic receptors in vascular smooth muscle cells. Am J Physiol. 1995;268(3 Pt 2):H1006-14.
69. Vittorio, T.J., et al., Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. Circulation, 2003. 107(2): p. 290-3. This study provides clinical evidence for the crosstalk phenomenon between the AT1R and the α-1R in patients with chronic heart failure. (Pubitemid 36135226)
70. Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-55. (Pubitemid 26152713)
71. Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. (Pubitemid 36835815)
72. Horiuchi M, et al. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res. 1999;84(8):876-82. (Pubitemid 29196731)
73. ClinicalTrials.gov. Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT) [NCT00894387]. Available at http://clinicaltrials.gov/ct2/show/NCT00894387. Accessed March 2012.
74. ClinicalTrials.gov. Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in PatientsWith Chronic Heart Failure (ATMOSPHERE) [NCT00853658]. Available at http://clinicaltrials.gov/ct2/ show/NCT00853658. Accessed March 2012.
75. ClinicalTrials.gov. The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE) [NCT01432106]. Available at http: //clinicaltrials.gov/ct2/show/NCT01432106. Accessed March 2012.